We would love to hear your thoughts about our site and services, please take our survey here.
I guess that’s a no from trans.
Oh well. As you were folks.
Go for it trans, the floor is yours....
Wonder if slave2trade is going to tell us when it’s NT to sell?
Oooh a March AGM this year... fun!
Easy to buy online for 0.412p
You’ll be gone by 0.5p
More very relevant emerging research on the importance of inflammasomes in treating respiratory diseases. In particular the role of NLRP3 which NFX research specifically targets.
Published 5th Jan 2024.
'The role of inflammasomes in human diseases and their potential as therapeutic targets'
Respiratory disorders
Inflammasomes are implicated in the pathogenesis of several respiratory disorders, including asthma, chronic obstructive pulmonary disease (COPD), pulmonary infection, pulmonary fibrosis, and acute respiratory distress syndrome (ARDS). As a result, inflammasomes have become a significant focus for research aimed at developing new diagnostic biomarkers and therapeutic avenues in pulmonary diseases and other respiratory disorders.
Asthma is a chronic inflammatory disease of the airways that affects inflammatory cells and cytokines in the lungs.238 Exposure to industrial products, microbes, or other allergens induces reversible limitations in airflow into and out of the lungs, as well as airway hyper-responsiveness. Persistent airway inflammation causes structural changes in airway tissues, known as airway remodeling, resulting in nonreversible airway obstruction and progressive loss of lung function. There is increasing evidence that NLRP3 inflammasome plays a role in asthma.
The end result of inflammatory pulmonary diseases is fibrosis. The NLRP3 inflammasome mediates pulmonary fibrosis through the IL-1β-IL-1Rs-MyD88-NF-κB signaling pathway.263 Moreover, studies also found that NLRP3 inflammasome could transform lung endothelial cells into epithelial-mesenchymal transition, promoting pulmonary fibrosis. Caspase-1 and IL-1β play vital roles in pulmonary fibrogenesis. Caspases-1enzyme cleavages the pro-IL-1β and allows secretion of IL-1β.264 Elevated IL-1β has a profibrotic effect, and usually occurs in combination with higher expression of IL-1Rs in fibrogenesis.265 A study on mouse primary lung fibroblasts showed that the NLRP3 inflammasome increases IL-1β production, leading to lung fibrosis when induced by bleomycin.266 Collectively, these investigations have helped to clarify the role of inflammasomes in the development of pulmonary fibrosis and may lead to the discovery of new treatment targets for various respiratory disorders.
https://www.nature.com/articles/s41392-023-01687-y
0.407p online quotes to buy on HL.
This weeks rise is most welcome and a good start to the year. The lack of sells into strength are also a welcome relief.
It’s clear that the results are somewhat linked to this on a number of fronts.
Firstly, they confirmed the company is a going concern, this is something that certain posters have been saying for the past year would never be achieved. What’s more is that this was signed off by the auditors, again something certain posters said would never happen.
The removal of this doubt is key for some to invest.
Second, the company cash position was made clear. Yes, it’s not huge but again some posters were sowing the seeds of doubt saying there would be a placing back in July and then in December, none of which materialised.
Thirdly. The results explicitly state that nxp004 is under discussion with potential partners, this is the first time this has been seen in writing.
They have also indicated that they are open to co-development of products with third parties to extend patent protection for products. Whilst not a priority this could be a revenue generating business model that supplements the company whilst moving NFX assets forward with a partner.
There’s lots to pick up on from the results which are the primary source of the rally from this week.
“ £22k in transactions = £320k rise in capital ”
Awww bless… you believe the monetary value of trades determines Mcap. Lol!
Because there were more buys than sells.
Are you unhappy that the sp has gone up?
Happy enough with this first week of the year.
Good job we were never anchored to 0.3
Well done on your average whimax
Nice end to the day, shows how a little buying can put pressure on the sp with Lanstead out of the way.
I get the feeling that interest in nxp004 is further along than 002.
"These attributes position NXP004 for applications in line-extensions for the currently marketed product, or for possible development in future first-to-generic products. The Company has commenced discussions with potential commercialisation partners."
Its in the results, the non-execs are not taking a salary. They will likely receive a payment based on a percentage of any licensing deal done.
Don’t know much about Moderna, what makes you think of them?
Also Julian and Maddie are not taking any salary for the next year.